Lumira Ventures

Developer of the Carillon Mitral Contour System®; presented data confirming acute hemodynamic efficacy and reported pivotal trial activity and multiple financings (data presentation April 26, 2019).

#Medical device (structural heart / mitral contour system)

Provider of optical sensing products for cardiology; reported record consolidated revenues for Q2 2019 and ongoing commercial milestones.

#Medical device (optical pressure guidewire / cardiology diagnostics)

Developer of the TransPyloric Shuttle® (TPS®). Reported FDA approval of the TPS device for one‑year device treatment (April 23, 2019) and has presented pivotal trial data.

#Medical device (obesity treatment device)

Developer of the Edison® Histotripsy System; reported FDA De Novo clearance, first patients treated and secured financing, including a $54M Series C (April 2019).

#Medical device / therapeutic (histotripsy systems)

Announced Series B financing to support commercial expansion of the HyperVue™ imaging system; Lumira participated in the round.

#Medical imaging (coronary artery disease imaging)

Clinical-stage company developing charged sodium channel blockers for refractory chronic cough; reported dosing the first patient in a Phase 2b chronic cough study and Lumira announced an investment.

#Biopharmaceuticals (small molecule sodium channel blockers)

Completed enrollment in a Phase 2 trial of CYR-064 for post-viral smell loss and announced Series B financing.

#Regenerative medicine (treatments for smell loss / hyposmia)

Developer of tolerogenic nanoparticle therapies for autoimmune disease and Type 1 diabetes; secured IND clearance and closed a $105M Series A financing co-led by Lumira.

#Biopharmaceuticals (tolerogenic nanoparticle therapies / autoimmune / Type 1 Diabetes)

Acquired a portfolio of nucleoside analogs and reported Phase 2 results for TPN-101; received Fast Track designation for TPN-101.

#Biopharmaceuticals (neurodegenerative / oral therapies)

Reported preliminary safety and dosimetry results from the single-dose portion of a Phase 1 study of FPI‑1434.

#Biopharmaceuticals (oncology)

Lumira joined a financing syndicate for Notch Therapeutics, a company developing allogeneic gene‑modified T cell therapies.

#Cell therapy (allogeneic T cell technology)

Closed a US$3.6M seed financing round with Lumira participating.

#Biopharmaceuticals

Completed Phase 1a solid tumor trial enrollment and closed a Series C financing; reported multiple clinical milestones including first patient dosed in Phase 1b myelofibrosis and initiation of Phase 2a trials (2019 announcements).

#Biopharmaceuticals (oncology / fibrosis)

Reported Phase 2b enrollment and regulatory approvals for planned clinical studies; involved in corporate transactions including a share exchange agreement with Stellar Biotechnologies (March 2019).

#Biopharmaceuticals (dermatology)

Raised $62M in Series B preferred stock financing to support Phase 3 development of STS101 (April 24, 2019) and later completed an IPO.

#Biopharmaceuticals (migraine)

Commercial launch of the 14‑day Carnation Ambulatory Monitor (CAM™) patch; raised $35.5M Series B financing with Lumira participating (April 16, 2019).

#Medical devices / diagnostics (ambulatory cardiac monitoring)

Developer of the InterAtrial Shunt Device (IASD®). Reported FDA Breakthrough Device designation, initiation of global clinical trials and an exclusive right-to-acquire arrangement with Edwards Lifesciences (March 2019).

#Medical device (structural heart / interatrial shunt)

Announced additional funding rounds to advance antifungal therapy programs; Lumira participated in financing activity.

#Biopharmaceuticals (antifungal therapies)

Announced senior management expansions and development of a non-viral gene delivery platform.

#Gene therapy / biotechnology

Initiated first‑in‑human Phase 1 study of ATI‑2173, a liver-targeted small molecule for hepatitis B.

#Biopharmaceuticals (antiviral therapies)

Reported Phase 2b trial results for Staccato® alprazolam and ongoing registrational studies; presented data at professional meetings (2019).

#Biopharmaceuticals (neurology / seizure therapy)

Expanded product portfolio and reported revenue milestones, including a reported 512% year-over-year revenue increase in a company update (March 2019).

#Specialty pharmaceuticals